The post BASIS Secures $35 Million in Strategic Capital to Bring Institutional HFT Tech to Retail Staking Markets appeared on BitcoinEthereumNews.com. New platformThe post BASIS Secures $35 Million in Strategic Capital to Bring Institutional HFT Tech to Retail Staking Markets appeared on BitcoinEthereumNews.com. New platform

BASIS Secures $35 Million in Strategic Capital to Bring Institutional HFT Tech to Retail Staking Markets

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com
  • New platform backed by Base58 Labs creates a ‘Liquidity Layer’ model, rejecting typical operational burn rates.

  • Proprietary ‘Base58 Hyper-Latency Engine (BHLE)’ and compliance systems transferred to ensure zero-slippage execution.

  • Targeting H2 2026 launch to redefine safety standards for individual investors.

ZURICH – February 18, 2026 – A new standard for digital asset infrastructure is set to emerge as BASIS, the strategic arm of renowned blockchain research firm Base58 Labs, confirmed a massive $35 million Pre-Series A capital injection today. Unlike traditional startup funding used for expansion or marketing, this capital is designated entirely as a ‘Strategic Liquidity Reserve,’ aiming to guarantee institutional-grade solvency from day one.

The move signifies a major shift in the European fintech sector, as Base58 Labs moves to commercialize its high-performance research. Known for its foundational work on Bitcoin protocols and security since the industry’s early days, Base58 Labs is now bridging the gap between professional trading desks and the retail market.

Commercializing ‘High-Precision’ R&D While many platforms focus on user acquisition, BASIS is built on a foundation of proprietary technology. The company revealed that the $35 million valuation is supported by the direct transfer of Base58 Labs’ ‘Base58 Hyper-Latency Engine (BHLE).’

Originally designed for institutional HFT architectures, BHLE captures micro-price discrepancies with nanosecond-level precision. Crucially, it incorporates a ‘Market Neutral’ algorithm to eliminate directional risk, a capability proven through thousands of high-intensity stress tests.

Safety Over Speculation In alignment with stringent global regulations like MiCA, BASIS has integrated an ‘Enterprise-Grade Risk Management System.’ This system is designed to eliminate the common security pitfalls of traditional DeFi services.

The CEO of BASIS emphasized the platform’s unique starting position:

BASIS is currently in the final stages of Tier-1 security audits and plans to open its services to the public in the second half of 2026.

About Base58 Labs Base58 Labs specializes in advanced blockchain infrastructure and algorithmic trading research. By solving critical challenges in protocol security and execution latency, the group continues to bridge the divide between traditional finance and the decentralized economy.

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

Source: https://cryptodaily.co.uk/2026/02/basis-secures-35-million-in-strategic-capital-to-bring-institutional-hft-tech-to-retail-staking-markets

Market Opportunity
Hashflow Logo
Hashflow Price(HFT)
$0.01543
$0.01543$0.01543
-1.34%
USD
Hashflow (HFT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09